Literature DB >> 1901229

Modulation of bovine luteal cell synthetic capacity by interferon-gamma.

D L Fairchild1, J L Pate.   

Abstract

Previous work from our laboratory has demonstrated that major histocompatibility complex (MHC) antigens are expressed on cultured bovine luteal cells following exposure to the T lymphocyte-derived cytokine, interferon-gamma (IFN-gamma). In light of these actions of IFN-gamma, it was of interest to investigate the effects of this cytokine on other aspects of luteal function. Therefore, bovine luteal cells were cultured for 7 days in the presence or absence of IFN-gamma, and luteal progesterone (P4), prostaglandin F2 alpha (PGF2 alpha), and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) production were evaluated. After a 24-h exposure to IFN-gamma (100 U), both PGF2 alpha and 6-keto-PGF1 alpha production were decreased approximately 50% (p less than 0.05). However, as time in culture progressed, IFN-gamma markedly increased the synthesis of both prostaglandins approximately 400% above controls (p less than 0.05). Stimulation of prostaglandin production by IFN-gamma was abrogated by the addition of exogenous P4. During the period of IFN-gamma-stimulated prostaglandin synthesis, LH-stimulated P4 production was inhibited by IFN-gamma treatment. However, the suppression of P4 production by IFN-gamma was not mediated by the increase in prostaglandins since concomitant treatment with indomethacin did not reverse the inhibition of steroidogenesis. These results suggest that IFN-gamma, in addition to an indirect role in promoting immune response mechanisms, may also directly affect luteal function by enhancing luteal prostaglandin synthesis and by inhibiting luteal steroidogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901229     DOI: 10.1095/biolreprod44.2.357

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  8 in total

Review 1.  History, insights, and future perspectives on studies into luteal function in cattle.

Authors:  Cecily V Bishop; Vimal Selvaraj; David H Townson; Joy L Pate; Milo C Wiltbank
Journal:  J Anim Sci       Date:  2022-07-01       Impact factor: 3.338

2.  Acid sphingomyelinase involvement in tumor necrosis factor alpha-regulated vascular and steroid disruption during luteolysis in vivo.

Authors:  Luiz E Henkes; Brian T Sullivan; Maureen P Lynch; Richard Kolesnick; Danielle Arsenault; Mark Puder; John S Davis; Bo R Rueda
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-27       Impact factor: 11.205

3.  Expression of costimulatory molecules in the bovine corpus luteum.

Authors:  Matthew J Cannon; John S Davis; Joy L Pate
Journal:  Reprod Biol Endocrinol       Date:  2007-01-31       Impact factor: 5.211

4.  Luteal Lipids Regulate Progesterone Production and May Modulate Immune Cell Function During the Estrous Cycle and Pregnancy.

Authors:  Camilla H K Hughes; Remy Bosviel; John W Newman; Joy L Pate
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-04       Impact factor: 5.555

Review 5.  Perturbations in Lineage Specification of Granulosa and Theca Cells May Alter Corpus Luteum Formation and Function.

Authors:  Mohamed A Abedel-Majed; Sarah M Romereim; John S Davis; Andrea S Cupp
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-29       Impact factor: 6.055

6.  CXCL12 May Drive Inflammatory Potential in the Ovine Corpus Luteum During Implantation.

Authors:  Stacia Z McIntosh; Kelsey E Quinn; Ryan L Ashley
Journal:  Reprod Sci       Date:  2021-11-09       Impact factor: 3.060

7.  Signaling mechanisms in tumor necrosis factor alpha-induced death of microvascular endothelial cells of the corpus luteum.

Authors:  James K Pru; Maureen P Lynch; John S Davis; Bo R Rueda
Journal:  Reprod Biol Endocrinol       Date:  2003-02-11       Impact factor: 5.211

Review 8.  Regulation of intraluteal production of prostaglandins.

Authors:  Milo C Wiltbank; Joseph S Ottobre
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.